Why the study?
Do novel oral anticoagulants reduce healthcare costs compared to warfarin in patients with pulmonary embolism?
Do novel oral anticoagulants reduce healthcare costs compared to warfarin in patients with pulmonary embolism?
Maintenance therapy with novel oral anticoagulants is associated with lower direct and indirect healthcare costs compared to warfarin for patients with pulmonary embolism.
Answers are grounded in this paper and cite their sources.
May inform local PE anticoagulant selection amid cost pressures; leaves open generalizability beyond this retrospective cohort.
INTRODUCTION: Recently, novel oral anticoagulants (rivaroxaban, dabigatran, apixaban) have been approved for pulmonary embolism (PE) treatment. Each anticoagulant used during initial and maintenance therapy has direct and indirect costs for healthcare systems. Demonstrating the costs of treatment with different anticoagulants in a specific patient group will be helpful for clinicians determining treatment strategies. MATERIALS AND METHODS: Retrospective data of 118 patients with PE who were hospitalized and treated with warfarin for at least 3 months were evaluated. Direct medical and nonmedical costs were calculated. True costs with warfarin and modeled costs with rivaroxaban, dabigatran, apixaban and enoxaparine were calculated and compared for maintenance therapy. Estimated costs of initial and maintenance treatment with different anticoagulants were compared for the 49 patients with low complication risk. RESULT: The average total cost of maintenance treatment with warfarin was found to be higher than the novel oral anticoagulants (€286.5 for warfarin, €233.3 for rivaroxaban, €231.7 for dabigatran, and €229.6 for apixaban). In patients with low complication risk, who could be treated without hospitalization, alternative treatment regiments were found to cost less than warfarin treatment (€883.1 for warfarin, €254.3 for rivaroxaban, €238 for apixaban, and €810.6 for enoxaparine). CONCLUSIONS: Maintenance therapy with novel oral anticoagulant costs less than warfarin treatment. In patients with lower complication risks, alternative regimens that do not require hospitalization could cost less.
No takes yet. Share an insight, caveat, or question.
Türk et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: